Auro-Dapagliflozin

ODB Formulary Therapeutic Classification

• 68:20:02 Oral Anti-Diabetic Agents

Therapeutic Note

Dapagliflozin 5 mg Tablet: Added on to metformin for patients: - Who have inadequate glycemic control on metformin and - Who have a contraindication or intolerance to a sulfonylurea or - For whom insulin is not an option. Added on to a sulfonylurea for patients: - Who have inadequate glycemic control on a sulfonylurea and - Who have a contraindication or intolerance to metformin or - For whom insulin is not an option. For the treatment of adult patients with New York Heart Association (NYHA) class II and III heart failure, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) [Left ventricular ejection fraction (LVEF less than or equal to 40%)]. Standard of care therapies include beta-blockers, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), plus a mineralocorticoid receptor antagonist.

ATC Code

A10BK01

Interchangeable Products

 

LU Clinical Criteria

NO  

EAP Criteria

NO

Product Monograph

View Monograph